Last reviewed · How we verify
ADL5859
ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis.
ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis. Used for Complicated urinary tract infections, Complicated intra-abdominal infections.
At a glance
| Generic name | ADL5859 |
|---|---|
| Also known as | ADL-5859 |
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | carbapenem antibiotic |
| Target | transpeptidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
ADL5859 works by inhibiting the enzyme transpeptidase, which is essential for bacterial cell wall formation. This leads to the disruption of the bacterial cell wall, ultimately causing cell lysis and death. ADL5859 has shown promise in treating various bacterial infections.
Approved indications
- Complicated urinary tract infections
- Complicated intra-abdominal infections
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee (PHASE2)
- Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction (PHASE2)
- Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: